![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1551486 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of MAP3K2 mRNA | CTD | PMID:22206623 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1551486 | 6480464 | Tetrachlorodibenzodioxin affects the expression of MAP3K2 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MAP3K2 mRNA | CTD | PMID:33387578 | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 3-chloropropane-1,2-diol | increases expression | EXP | | 6480464 | alpha-Chlorohydrin results in increased expression of MAP3K2 mRNA | CTD | PMID:28522335 | aflatoxin B1 | decreases methylation | ISO | RGD:1354206 | 6480464 | Aflatoxin B1 results in decreased methylation of MAP3K2 gene | CTD | PMID:27153756 | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of MAP3K2 mRNA | CTD | PMID:16483693 | aristolochic acid | decreases expression | ISO | RGD:1354206 | 6480464 | aristolochic acid I results in decreased expression of MAP3K2 mRNA | CTD | PMID:33212167 | benzo[a]pyrene | decreases expression | ISO | RGD:1354206 | 6480464 | Benzo(a)pyrene results in decreased expression of MAP3K2 mRNA | CTD | PMID:20106945, PMID:21632981 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of MAP3K2 mRNA | CTD | PMID:25181051, PMID:29097150 | bisphenol A | multiple interactions | ISO | RGD:1354206 | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of MAP3K2 gene | CTD | PMID:31601247 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of MAP3K2 mRNA | CTD | PMID:34947998 | cadmium dichloride | increases expression | ISO | RGD:1354206 | 6480464 | Cadmium Chloride results in increased expression of MAP3K2 mRNA | CTD | PMID:32512071 | carbon nanotube | decreases expression | ISO | RGD:1551486 | 6480464 | Nanotubes, Carbon analog results in decreased expression of MAP3K2 mRNA | CTD | PMID:25554681 | CGP 52608 | multiple interactions | ISO | RGD:1354206 | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to MAP3K2 gene] | CTD | PMID:28238834 | cisplatin | multiple interactions | ISO | RGD:1354206 | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of MAP3K2 mRNA | CTD | PMID:27392435 | copper atom | multiple interactions | ISO | RGD:1354206 | 6480464 | [Chelating Agents binds to Copper] which results in increased expression of MAP3K2 mRNA | CTD | PMID:30911355 | copper(0) | multiple interactions | ISO | RGD:1354206 | 6480464 | [Chelating Agents binds to Copper] which results in increased expression of MAP3K2 mRNA | CTD | PMID:30911355 | copper(II) sulfate | increases expression | ISO | RGD:1354206 | 6480464 | Copper Sulfate results in increased expression of MAP3K2 mRNA | CTD | PMID:19549813 | crocidolite asbestos | affects expression | ISO | RGD:1354206 | 6480464 | Asbestos, Crocidolite affects the expression of MAP3K2 mRNA | CTD | PMID:17331233 | dioxygen | multiple interactions | ISO | RGD:1551486 | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of MAP3K2 mRNA | CTD | PMID:30529165 | dorsomorphin | multiple interactions | ISO | RGD:1354206 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | entinostat | multiple interactions | ISO | RGD:1354206 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA | CTD | PMID:27188386 | fluoranthene | multiple interactions | ISO | RGD:1551486 | 6480464 | [1-methylanthracene co-treated with fluoranthene] results in increased expression of MAP3K2 mRNA | CTD | PMID:28329830 | formaldehyde | increases expression | ISO | RGD:1354206 | 6480464 | Formaldehyde results in increased expression of MAP3K2 mRNA | CTD | PMID:23649840 | fulvestrant | multiple interactions | ISO | RGD:1354206 | 6480464 | [bisphenol A co-treated with Fulvestrant] results in decreased methylation of MAP3K2 gene | CTD | PMID:31601247 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of MAP3K2 mRNA | CTD | PMID:33387578 | hydrogen cyanide | decreases expression | ISO | RGD:1551486 | 6480464 | Hydrogen Cyanide results in decreased expression of MAP3K2 mRNA | CTD | PMID:33914522 | hydrogen peroxide | increases expression | ISO | RGD:1354206 | 6480464 | Hydrogen Peroxide results in increased expression of MAP3K2 mRNA | CTD | PMID:18951874 | isoprenaline | multiple interactions | EXP | | 6480464 | [Isoproterenol co-treated with POSTN protein] results in decreased expression of MAP3K2 mRNA | CTD | PMID:30303030 | isoprenaline | decreases expression | EXP | | 6480464 | Isoproterenol results in decreased expression of MAP3K2 mRNA | CTD | PMID:30303030 | metformin | multiple interactions | ISO | RGD:1354206 | 6480464 | [Paclitaxel co-treated with Metformin] results in decreased expression of MAP3K2 mRNA | CTD | PMID:29309887 | methyl methanesulfonate | increases expression | ISO | RGD:1354206 | 6480464 | Methyl Methanesulfonate results in increased expression of MAP3K2 mRNA | CTD | PMID:23649840 | miconazole | decreases expression | ISO | RGD:1551486 | 6480464 | Miconazole results in decreased expression of MAP3K2 mRNA | CTD | PMID:27462272 | nickel sulfate | multiple interactions | ISO | RGD:1551486 | 6480464 | [MAP3K1 protein co-treated with MAP3K2 protein] affects the susceptibility to nickel sulfate | CTD | PMID:18467339 | paclitaxel | multiple interactions | ISO | RGD:1354206 | 6480464 | [Paclitaxel co-treated with Metformin] results in decreased expression of MAP3K2 mRNA | CTD | PMID:29309887 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of MAP3K2 mRNA | CTD | PMID:33387578 | phenobarbital | decreases expression | ISO | RGD:1551486 | 6480464 | Phenobarbital results in decreased expression of MAP3K2 mRNA | CTD | PMID:23091169 | phenylmercury acetate | decreases expression | ISO | RGD:1354206 | 6480464 | Phenylmercuric Acetate results in decreased expression of MAP3K2 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | RGD:1354206 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA | CTD | PMID:27188386 | pirinixic acid | decreases expression | ISO | RGD:1551486 | 6480464 | pirinixic acid results in decreased expression of MAP3K2 mRNA | CTD | PMID:20813756 | potassium cyanide | decreases expression | ISO | RGD:1551486 | 6480464 | Potassium Cyanide results in decreased expression of MAP3K2 mRNA | CTD | PMID:33914522 | resveratrol | multiple interactions | ISO | RGD:1354206 | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of MAP3K2 mRNA | CTD | PMID:23557933 | SB 431542 | multiple interactions | ISO | RGD:1354206 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | increases expression | ISO | RGD:1354206 | 6480464 | Silicon Dioxide analog results in increased expression of MAP3K2 mRNA | CTD | PMID:23806026 | silver atom | increases expression | ISO | RGD:1354206 | 6480464 | Silver results in increased expression of MAP3K2 mRNA | CTD | PMID:26014281 | silver(0) | increases expression | ISO | RGD:1354206 | 6480464 | Silver results in increased expression of MAP3K2 mRNA | CTD | PMID:26014281 | sodium arsenate | decreases expression | ISO | RGD:1551486 | 6480464 | sodium arsenate results in decreased expression of MAP3K2 mRNA | CTD | PMID:21795629 | sodium arsenate | increases expression | ISO | RGD:1551486 | 6480464 | sodium arsenate results in increased expression of MAP3K2 mRNA | CTD | PMID:21795629 | succimer | multiple interactions | ISO | RGD:1354206 | 6480464 | [Succimer co-treated with Magnetite Nanoparticles] results in increased expression of MAP3K2 mRNA | CTD | PMID:26378955 | succimer | multiple interactions | ISO | RGD:1551486 | 6480464 | [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of MAP3K2 mRNA | CTD | PMID:26378955 | sunitinib | increases expression | ISO | RGD:1354206 | 6480464 | Sunitinib results in increased expression of MAP3K2 mRNA | CTD | PMID:31533062 | testosterone | increases expression | ISO | RGD:1354206 | 6480464 | Testosterone results in increased expression of MAP3K2 mRNA | CTD | PMID:33359661 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of MAP3K2 mRNA | CTD | PMID:31150632 | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of MAP3K2 mRNA | CTD | PMID:34492290 | torcetrapib | increases expression | ISO | RGD:1354206 | 6480464 | torcetrapib results in increased expression of MAP3K2 mRNA | CTD | PMID:23228038 | troglitazone | decreases expression | ISO | RGD:1551486 | 6480464 | troglitazone results in decreased expression of MAP3K2 mRNA | CTD | PMID:28973697 | valproic acid | multiple interactions | ISO | RGD:1354206 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP3K2 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of MAP3K2 mRNA | CTD | PMID:29427782 | valproic acid | affects splicing | EXP | | 6480464 | Valproic Acid affects the splicing of MAP3K2 mRNA | CTD | PMID:29427782 | valproic acid | decreases expression | ISO | RGD:1354206 | 6480464 | Valproic Acid results in decreased expression of MAP3K2 mRNA | CTD | PMID:23179753 more ... | vanadium atom | increases expression | ISO | RGD:1354206 | 6480464 | Vanadium results in increased expression of MAP3K2 mRNA | CTD | PMID:19000753 | vanadium(0) | increases expression | ISO | RGD:1354206 | 6480464 | Vanadium results in increased expression of MAP3K2 mRNA | CTD | PMID:19000753 | vorinostat | decreases expression | ISO | RGD:1354206 | 6480464 | vorinostat results in decreased expression of MAP3K2 mRNA | CTD | PMID:27188386 | zoledronic acid | decreases expression | ISO | RGD:1354206 | 6480464 | zoledronic acid results in decreased expression of MAP3K2 mRNA | CTD | PMID:20977926 | |